The gene editing technique CRISPR has been in the limelight after scientists reported they had used it to safely remove disease in human embryos for the first time. This follows a “CRISPR craze” over the last couple of years, with the number of academic publications on the topic growing steadily.
There are good reasons for the widespread attention to CRISPR. The technique allows scientists to “cut and paste” DNA more easily than in the past. It is being applied to a number of different peaceful areas, ranging from cancer therapies to the control of disease carrying insects.
Some of these applications – such as the engineering of mosquitoes to resist the parasite that causes malaria – effectively involve tinkering with ecosystems. CRISPR has therefore generated a number of ethical and safety concerns. Some also worry that applications being explored by defence organisations that involve “responsible innovation in gene editing” may send worrying signals to other states.
Concerns are also mounting that gene editing could be used in the development of biological weapons. In 2016, Bill Gates remarked that “the next epidemic could originate on the computer screen of a terrorist intent on using genetic engineering to create a synthetic version of the smallpox virus”. More recently, in July 2017, John Sotos, of Intel Health & Life Sciences, stated that gene editing research could “open up the potential for bioweapons of unimaginable destructive potential”.
An annual worldwide threat assessment report of the US intelligence community in February 2016 argued that the broad availability and low cost of the basic ingredients of technologies like CRISPR makes it particularly concerning.

Smallpox virus. CDC/ Fred Murphy
However, one has to be careful with the hype surrounding new technologies and, at present, the security implications of CRISPR are probably modest. There are easier, cruder methods of creating terror. CRISPR would only get aspiring biological terrorists so far. Other steps, such as growing and disseminating biological weapons agents, would typically be required for it to become an effective weapon. This would require additional skills and places CRISPR-based biological weapons beyond the reach of most terrorist groups. At least for the time being.
This does not mean that the hostile exploitation of CRISPR by non-state actors can be ignored. Nor can one ignore the likely role of CRISPR in any future state biological weapons programme.
International efforts
Fortunately, most states around the world regard biological warfare with particular abhorrence. There are already measures in place to prohibit and prevent the development of biological weapons. At the international level, this includes the Biological and Toxin Weapons Convention. Under this convention, states have agreed “never under any circumstances to acquire or retain biological weapons”.
This convention is imperfect and lacks a way to ensure that states are compliant. Moreover, it has not been adequately “tended to” by its member states recently, with the last major meeting unable to agree a further programme of work. Yet it remains the cornerstone of an international regime against the hostile use of biology. All 178 state parties declared in December of 2016 their continued determination “to exclude completely the possibility of the use of (biological) weapons, and their conviction that such use would be repugnant to the conscience of humankind”.
These states therefore need to address the hostile potential of CRISPR. Moreover, they need to do so collectively. Unilateral national measures, such as reasonable biological security procedures, are important. However, preventing the hostile exploitation of CRISPR is not something that can be achieved by any single state acting alone.
As such, when states party to the convention meet later this year, it will be important to agree to a more systematic and regular review of science and technology. Such reviews can help with identifying and managing the security risks of technologies such as CRISPR, as well as allowing an international exchange of information on some of the potential benefits of such technologies.
Most states supported the principle of enhanced reviews of science and technology under the convention at the last major meeting. But they now need to seize the opportunity and agree on the practicalities of such reviews in order to prevent the convention being left behind by developments in science and technology.
Biological warfare is not an inevitable consequence of advances in the life sciences. The development and use of such weapons requires agency. It requires countries making the decision to steer the direction of life science research and development away from hostile purposes. An imperfect convention cannot guarantee that these states will always decide against the hostile exploitation of biology. Yet it can influence such decisions by shaping an environment in which the disadvantages of pursuing such weapons outweigh the advantages.
James Revill received funding from the Economic and Social Research Council (ESRC) for his work on the Strategic Governance of Science and Technology (ES/K011324/1) and Science and Technology Reviews under the Biological Weapons Convention (RES-062-23-1192)


Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth
Kennedy Sets September Deadline to Uncover Autism Causes Amid Controversy
Bitcoin Reserves Hit 5-Year Low as $2.15B Exits Exchanges – Bulls Quietly Loading the Spring Below $100K
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Bitcoin Smashes $93K as Institutions Pile In – $100K Next?
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
Ethereum Ignites: Fusaka Upgrade Unleashes 9× Scalability as ETH Holds Strong Above $3,100 – Bull Run Reloaded
Morgan Stanley Boosts Nvidia and Broadcom Targets as AI Demand Surges
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 



